Palbociclib - Biotx.ai
Latest Information Update: 23 Nov 2022
At a glance
- Originator Biotx.ai
- Class 2 ring heterocyclic compounds; Antineoplastics; Antivirals; Cyclopentanes; Ketones; Monoclonal antibodies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 07 Nov 2022 Biotx.ai withdraws a phase II trial in COVID-2019 infections in Germany due to due to challenges in patient enrollment(NCT05371275)
- 25 May 2022 Biotx.ai enters into a commercial partnership before May 2022 with an unknown organization for the development of Palbociclib in COVID-2019 infections (Biotx.ai pipeline, May 2022)
- 21 Apr 2022 Phase-II clinical trials in COVID-2019 infections in Germany (PO) (NCT05371275)